Anti-Cancer Potential of Cyclooxygenase-2-InhibitorsJournal: International Journal of Science and Research (IJSR) (Vol.11, No. 4)
Publication Date: 2022-04-05
Authors : B. Baslur Rahman;
Page : 404-409
Keywords : Cyclooxygenase-2-Inhibitor; NSAID; Carcinogenesis; Breast cancer; Apoptosis; Celecoxib;
Cyclooxygenase-2-Inhibitor is mostly used in Non-Steroidal Anti-Inflammatory Drug [NSAID] They are the most often used class of medications, primarily in the treatment of degenerative joint illness, rheumatic diseases, metabolic disorders, cardiovascular disturbances, infections, and other pain and inflammation-related diseases. Although long-term NSAID use was found to be associated with a decreased risk of developing breast cancer in Women. The activity of COX-2-Inhibitor is confirmed with reduced Carcinogenesis. COX-2 inhibition appears to prevent the development of breast tumours in women with breast cancer. Nonselective inhibitors like indomethacin, flurbiprofen, and aspirin, for example, have been shown to lessen the frequency of carcinogen-induced tumors. Furthermore, COX-2 inhibitors that are preferred or selective, such as celecoxib and nimesulide, have been shown to delay carcinogenesis and reduce disease incidence.
Other Latest Articles
Last modified: 2022-05-14 21:04:25